<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 11, 1999
COLLATERAL THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
000-24505 33-0661290
(Commission File Number) (IRS Employer Identification No.)
11622 El Camino Real, San Diego, CA 91230
(Address of principal executive offices) (Zip Code)
(858) 794-3400
(Registrant's telephone number, including area code)
<PAGE>
ITEM 5. Other Events
Attached hereto is a press release issued by the registrant on August
12, 1999.
ITEM 7. Financial and Exhibits.
(C) EXHIBITS.
EXHIBIT NO. DESCRIPTION
- ---------- -----------
99.1 Press Release, dated August 12, 1999
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has caused this report to be signed on its behalf by the
undersigned.
COLLATERAL THERAPEUTICS, INC.
Date: August 12, 1999 /s/ Christopher J. Reinhard
---------------------------
Christopher J. Reinhard
Chief Operating and Financial Officer
(Principal Financial and Accounting Officer)
-2-
<PAGE>
Exhibit 99.1
Christopher J. Reinhard Audra Nass
Chief Operating and Financial Officer Nass Communications Group
Direct Dial: (858) 794-3420 Direct Dial: (415) 431-1747
FOR IMMEDIATE RELEASE
COLLATERAL THERAPEUTICS ANNOUNCES $33.9 MILLION PRIVATE PLACEMENT
SAN DIEGO, California - August 12, 1999 -- Collateral Therapeutics, Inc.
(Nasdaq: CLTX) today announced the completion of a $33.9 million private
placement covering the sale of 2,150,000 shares of unregistered common stock
to selected institutional and accredited investors. The securities sold in
this private placement have not been registered under the Securities Act of
1933 and may not be offered or sold in the United States in the absence of an
effective Registration Statement or exemption from registration requirements.
The net proceeds of this financing are intended to be used to accelerate
development of Collateral's non-surgical gene therapy product candidates for
cardiovascular disease and to provide additional working capital for other
corporate purposes.
Statements in this press release that are not strictly historical may be
"forward-looking" statements, which involve risks and uncertainties. There
can be no assurance that Collateral Therapeutics will be able to commercially
develop cardiovascular gene therapy products and that necessary regulatory
approvals will be obtained or that any clinical trials will be successful.
The actual results may differ from those described in this press release due
to risks and uncertainties that exist in the Company's operations and
business environment, including, without limitation, the Company's early
stage of product development and of gene therapies, its dependence upon
proprietary technology, current competition, history of operating losses and
accumulated deficits, the Company's reliance on collaborative relationships,
and uncertainties related to clinical trials, safety, efficacy, the ability
to obtain the appropriate regulatory approvals, patent protection, market
acceptance, as well as other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission. The Company
undertakes no obligation to release publicly the results of any revisions to
these forward-looking statements to reflect events or circumstances arising
after the date hereof.
